Elevated level of cyclin D1 in mos-transformed cells

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1199-1202

  Yang, Yandan ^a   Pham, Chau D ^a   Arlinghaus, Ralph B ^a   Khillan, Jaspal S ^b   Singh, Balraj ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell cycle perturbation; Cellular transformation; Mitogenic signaling; Mos oncogene

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE G1 PHASE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

EID: 0031966638     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1199     Document Type: Article

References (35)

1. Van Beveren C, van Straaten F, Galleshaw JA and Verma IM: Nucleotide sequence of the genome of a murine sarcoma virus. Cell 370: 65-68, 1981.
2. mos. Virology 143: 321-333, 1985.
3. Sagata N, Oskarsson M, Copeland T, Brumbaugh J and Vande Woude GF: Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes. Nature 335: 519-525, 1988.
4. Sagata N, Watanabe N, Vande Woude GF and Ikawa Y: The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs. Nature 342: 512-518, 1989.
5. Colledge WW, Carlton MBL, Udy GB and Evans MJ: Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs. Nature 370: 65-68, 1994.
6. Hashimoto N, Watanabe N, Furuta Y, Tamemoto H, Sagata N, Yokoyama K, Okazaki K, Nagayoshi M, Takeda N, Ikawa Y, and Aizawa S: Parthenogenetic activation of oocytes in c-mos-deficient mice. Nature 370: 68-71, 1994.
7. Pham CD, Rungta M, Chandler DS, Yang Y, Arlinghaus RB, Rajagopalan S, Schwartz MR and Singh B: Essential role of c-Mos in eggs: reduced fertility and ovarian neoplasm in antisense mos tansgenic mice. Int J Gynecol Cancer 7: 314-317, 1997.
8. Papkoff J, Verma IM and Hunter T: Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. Cell 29: 417-426, 1982.
9. Posada J, Yew N, Ahn NG, Vande Woude GF and Cooper JA: Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase in vitro. Mol Cell Biol 13: 2546-2553, 1993.
10. Nebreda AR and Hunt T: The c-mos proto-oncogene protein kinase turns on and maintains the activity of MAP kinase, but not MPF, in cell-free extracts of Xenopus oocytes and eggs. EMBO J 12: 1979-1986, 1993.
11. Nebreda AR, Hill C, Gomez N, Cohen P and Hunt T: The protein kinase Mos activates MAP kinase kinase in vitro and stimulates MAP kinase pathway in mammalian somatic cells in vivo. FEBS Lett 333: 183-187, 1993.
12. Pham CD, Arlinghaus RB, Zheng CF, Guan KL and Singh B: Characterization of MEK1 phosphorylation by the v-Mos protein. Oncogene 10: 1683-1688, 1995.
13. Chen M and Cooper JC: Ser-3 is important for regulating Mos interaction with and stimulation of mitogen-activated protein kinase kinase. Mol Cell Biol 151: 4727-4734, 1995.
14. Singh B and Arlinghaus RB: Mos and the cell cycle. In: Progress in Cell Cycle Research. Vol 3. Meijer L, Guidet S and Philippe M (eds.) Plenum Press, New York, chapter 20, pp251-259, 1997.
15. Fukusawa K, Murakami MS, Blair DG, Kuriyama R, Hunt T, Fischinger P and Vande Woude GF: Similarities between somatic cells overexpressing the mos oncogene and oocytes during meiotic interphase. Cell Growth Differ 5: 1093-1103, 1994.
16. Fukusawa K and Vande Woude GF: Mos overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. Proc Natl Acad Sci USA 92: 3430-3433, 1995.
17. Hamelin R, Planchon P, Singh B and Arlinghaus RB: Inhibition of viral mos gene expression in transformed cells restricts cells cycle progression through G1 and G2 phases. Int J Oncol 1: 513-523, 1992.
18. Sherr C: G1 phase progression: cycling on cue. Cell 79: 551-555, 1994.
19. Sauer K and Lehner CF: The role of cyclin E in the regulation of entry into S phase. Prog Cell Cycle Res 1: 125-139, 1995.
20. 1-to-S transition. Mol Cell Biol 15: 3463-3469, 1995.
21. mos encoded by the HT-1 strain of Moloney murine sarcoma virus has an associated protein kinase activity. Oncogene 3: 79-85, 1988.
22. Paules RS, Resnick J, Kasenally AB, Ernst MK, Donovan P and Vande Woude GF: Characterization of activated and normal mouse mos gene in murine 3T3 cells. Oncogene 7: 2489-2498, 1992.
23. Yang Y, Herrmann CH, Arlinghaus RB and Singh B: Inhibition of v-Mos kinase activity by protein kinase A. Mol Cell Biol 16: 800-809, 1996.
24. Gallick GE, Sparrow JT, Singh B, Maxwell SA, Stanker LH and Arlinghaus RB: Recognition of mos-related proteins with an antiserum to a peptide of the v-mos gene product. J Gen Virol 66: 945-955, 1985.
25. Hatakeyama M and Weinberg RA: The role of RB in cell cycle control. Prog Cell Cycle Res 1: 9-19, 1995.
26. Elledge SJ and Harper JW: Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852, 1994.
27. Khillan JS, Oskarsson MA, Propst F, Kuwubara T, Vande Woude GF and Westphal H: Defects in lens fiber differentiation are linked to c-mos overexpression in transgenic mice. Genes Dev 1: 1327-1335, 1987.
28. 1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci USA 93: 5941-5946, 1996.
29. 1 to complete the cell cycle. Proc Natl Acad Sci USA 91: 8022-8026, 1994.
30. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589-23597, 1995.
31. 1 progression in NIH 3T3 cells. Mol Cell Biol 15: 3654-3663, 1995.
32. MAPK pathway. J Biol Chem 271: 20608-20616, 1996.
33. Rhodes N, Innes CL, Propst F and Paules RS: Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKS. Oncogene 14: 3017-3027, 1997.
34. Afshari CA, Rhodes N, Paules RS and Mudryj M: Deregulation of specific E2F complexes by the v-mos oncogene. Oncogene 14: 3029-3038, 1997.
35. Lengyel E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M and Boyd D: Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 11: 2639-2648, 1995.